Abivax SA
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Abivax SA
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.
/ 
Frequently asked questions
To buy Abivax SA stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Abivax SA by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Abivax SA is ABVX:xpar. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Abivax SA has its primary listing on Euronext Paris. You can trade Abivax SA with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Abivax SA is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Abivax SA as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Abivax SA.